Abstract
Prodrugs for PI3K: A series of substituted analogues of the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002 were prepared and found to potently inhibit the isolated enzyme but not MCF7 cell proliferation. Two tetrazolyl-substituted analogues were further derivatized as prodrugs resulting in restoration of cell-based activity. These data provide a conceptual model for development of tumor-targeting prodrug forms of cell-impermeable PI3K inhibitors.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Cell Proliferation / drug effects
-
Chromones / chemical synthesis
-
Chromones / chemistry
-
Chromones / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Screening Assays, Antitumor
-
Humans
-
MCF-7 Cells
-
Molecular Structure
-
Morpholines / chemical synthesis
-
Morpholines / chemistry
-
Morpholines / pharmacology*
-
Phosphatidylinositol 3-Kinases / metabolism
-
Phosphoinositide-3 Kinase Inhibitors*
-
Prodrugs / chemical synthesis
-
Prodrugs / chemistry
-
Prodrugs / pharmacology*
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Structure-Activity Relationship
Substances
-
Antineoplastic Agents
-
Chromones
-
Morpholines
-
Phosphoinositide-3 Kinase Inhibitors
-
Prodrugs
-
Protein Kinase Inhibitors
-
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one